| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology [H. K., T. K., K. S., S. K., N. M., M. K.] and Dermatology [K. A., H. T., H. I.], Asahikawa Medical College, Asahikawa, 078, Japan
Tyrosinase is an antigen that is expressed by normal melanocytes as well as melanoma cells, against which responses by autologous T cells have been detected. Although CD4+ T cells play an important role in tumor immunity in animal tumor models, little information about CD4+ T-cell immunity against human tumors exists. Here, we report that CD4+ T cells from the peripheral blood of a patient with melanoma respond to synthetic peptides derived from nonmutated tyrosinase. T-cell clones were generated that recognized the tyrosinase p386–406 peptide when it was presented by the HLA-DR15 (DRB1*1501) molecule. The CD4+ T-cell clone also recognized autologous EBV-transformed B-lymphoblastoid cell lines that had been pulsed with the lysate of melanoma cells. The synthetic tyrosinase p386–406 peptide was capable of binding to HLA-DR15 (DRB1*1501) molecules on cell surface of DR15 homozygous cells. Thus, the finding that nonmutated tyrosinase peptides are immunogenic in a melanoma patient may provide the basis for the development of cancer immunotherapy, based on knowledge of synthetic tumor-associated peptide antigens.
1 To whom requests for reprints should be addressed, at Department of Pathology, Asahikawa Medical College, Nishikagura 4-5-3-11, Asahikawa, 078, Japan.
Received 4/10/97. Accepted 11/11/97.
This article has been cited by other articles:
|
|
 |
|
  C. L. Slingluff Jr, G. R. Petroni, W. Olson, A. Czarkowski, W. W. Grosh, M. Smolkin, K. A. Chianese-Bullock, P. Y. Neese, D. H. Deacon, C. Nail, et al. Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens J. Clin. Oncol., October 20, 2008; 26(30): 4973 - 4980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Lindsey, L. Gritz, R. Sherry, A. Abati, P. A. Fetsch, L. C. Goldfeder, M. I. Gonzales, K. A. Zinnack, L. Rogers-Freezer, L. Haworth, et al. Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma Clin. Cancer Res., April 15, 2006; 12(8): 2526 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lepage and R. Lapointe Melanosomal Targeting Sequences from gp100 Are Essential for MHC Class II-Restricted Endogenous Epitope Presentation and Mobilization to Endosomal Compartments Cancer Res., February 15, 2006; 66(4): 2423 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al. Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, R. Omiya, M. Ruiz, E. Huarte, P. Sarobe, J. J. Lasarte, M. Herraiz, B. Sangro, J. Prieto, F. Borras-Cuesta, et al. Identification of an Antigenic Epitope for Helper T Lymphocytes from Carcinoembryonic Antigen Clin. Cancer Res., October 1, 2002; 8(10): 3219 - 3225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Wang, J. Zhou, K. Zhu, A. I. Riker, F. M. Marincola, and R.-F. Wang Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells: Its Role in Extracellular Matrix Formation and Tumor Metastasis J. Exp. Med., June 3, 2002; 195(11): 1397 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, J. Lu, and E. Celis Identification of Helper T-Cell Epitopes That Encompass or Lie Proximal to Cytotoxic T-Cell Epitopes in the gp100 Melanoma Tumor Antigen Cancer Res., October 1, 2001; 61(20): 7577 - 7584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. McNeel, L. D. Nguyen, and M. L. Disis Identification of T Helper Epitopes from Prostatic Acid Phosphatase Cancer Res., July 1, 2001; 61(13): 5161 - 5167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Franco, X. D. Zhang, E. Van Berkel, J. E. Sanders, X. Y. Zhang, W. D. Thomas, T. Nguyen, and P. Hersey The Role of NF-{{kappa}}B in TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis of Melanoma Cells J. Immunol., May 1, 2001; 166(9): 5337 - 5345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chiari, G. Hames, V. Stroobant, C. Texier, B. Maillère, T. Boon, and P. G. Coulie Identification of a Tumor-specific Shared Antigen Derived From an Eph Receptor and Presented to CD4 T Cells on HLA Class II Molecules Cancer Res., September 1, 2000; 60(17): 4855 - 4863. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kobayashi, M. Wood, Y. Song, E. Appella, and E. Celis Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/neu Tumor Antigen Cancer Res., September 1, 2000; 60(18): 5228 - 5236. [Abstract] [Full Text]
|
|
|
|
|
|
S. Wang, S. Bartido, G. Yang, J. Qin, Y. Moroi, K. S. Panageas, J. J. Lewis, and A. N. Houghton A Role for a Melanosome Transport Signal in Accessing the MHC Class II Presentation Pathway and in Eliciting CD4+ T Cell Responses J. Immunol., December 1, 1999; 163(11): 5820 - 5826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo Cancer Res., October 1, 1999; 59(19): 4955 - 4963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, M. J. Pittet, C. Vonarbourg, D. Rimoldi, D. Lienard, D. Speiser, R. Dunbar, V. Cerundolo, J.-C. Cerottini, and P. Romero Analysis of the Cytolytic T Lymphocyte Response of Melanoma Patients to the Naturally HLA-A*0201-associated Tyrosinase Peptide 368-376 Cancer Res., August 1, 1999; 59(16): 4050 - 4055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chaux, V. Vantomme, V. Stroobant, K. Thielemans, J. Corthals, R. Luiten, A. M.M. Eggermont, T. Boon, and P. van der Bruggen Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes J. Exp. Med., March 1, 1999; 189(5): 767 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Tempero, M. L. VanLith, K. Morikane, G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth CD4+ Lymphocytes Provide MUC1-Specific Tumor Immunity In Vivo That Is Undetectable In Vitro and Is Absent in MUC1 Transgenic Mice J. Immunol., November 15, 1998; 161(10): 5500 - 5506. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
